Hyperhidrosis is a dermatological condition defined by excessive sweating beyond thermoregulatory needs with significant effects on patients' quality of life. Hyperhidrosis is categorized as primary or secondary: primary hyperhidrosis is mostly focal and idiopathic, whereas secondary hyperhidrosis is commonly generalized and caused by an underlying medical condition or use of medications. Various surgical and nonsurgical therapies exist for primary hyperhidrosis. Although botulinum toxin is one of the deadliest toxins known, when used in small doses, it is one of the most effective therapies for primary hyperhidrosis. Botulinum toxin injections are widely used as a second-line primary hyperhidrosis treatment option once topical treatment strategies have failed. This article provides an overview of the commercially available botulinum toxin formulations and their applications in the treatment of primary hyperhidrosis.Le texte complet de cet article est disponible en PDF.
Key words : abobotulinumtoxinA, axillary hyperhidrosis, botulinum neurotoxin, botulinum toxin, Clostridium bacteria, craniofacial hyperhidrosis, excessive sweating, incobotulinumtoxinA, onabotulinumtoxinA, palmar hyperhidrosis, plantar hyperhidrosis, primary hyperhidrosis, prabotulinumtoxinA, rimabotulinumtoxinB
Abbreviations used : BTX, FDA, HH, PHH
| Funding sources: None.
| Conflicts of interest: None disclosed.
| IRB approval status: Not applicable.